Skip to content
Back to search results

Cannabis Use Disorder Identification Test—Revised (CUDIT-R)

Introduced by
Adamson, Kay-Lambkin, Baker, Lewin, Thornton, Kelly, Sellman
Year
2010
Type
Self-report
Family
cannabis-use-screening
Font size

What does it do?

The CUDIT-R is a brief, 8-item self-report screening instrument developed to identify cannabis use disorder and hazardous cannabis use patterns.

Introduced by Adamson and colleagues in 2010 as a revision of the original CUDIT, the CUDIT-R improves brevity and screening efficiency while maintaining strong psychometric properties. It is designed for use in primary care, addiction treatment, and public health settings to detect problematic cannabis use and inform treatment allocation decisions.

The intuition behind the method

The CUDIT-R operationalizes cannabis use disorder as a pattern of use characterized by frequency of use, signs of dependence (tolerance, withdrawal), driving impairment, and consequences in social and occupational domains. The instrument recognizes that cannabis use exists on a continuum from abstinence to non-problematic occasional use to hazardous use to cannabis use disorder. By focusing on key indicators of problem use (frequency, dependence signs, behavioral consequences), the CUDIT-R captures the clinically relevant features of problematic cannabis use in a parsimonious manner.

History

The CUDIT-R was developed by Adamson and colleagues at the National Drug and Alcohol Research Centre in Australia and published in Drug and Alcohol Dependence in 2010. The revision was undertaken to improve upon the original CUDIT by reducing item count, simplifying language, and enhancing screening accuracy in diverse populations. The CUDIT-R has been validated in treatment-seeking and community samples and has been translated into multiple languages. It is freely available for clinical and research use.

When to use it

The CUDIT-R is appropriate for use in primary care offices, emergency departments, addiction treatment programs, occupational health services, and research settings as a rapid screening tool for cannabis use disorder. It is useful for individuals with recent or current cannabis use, including those in treatment for other substances. The CUDIT-R is particularly valuable in jurisdictions where cannabis is legal and use prevalence is high. It is less suitable as a population-based screening tool for non-cannabis-using populations; clinical suspicion or risk factors should prompt use.

Limitations and considerations

  • Screening instrument, not diagnostic; cannot establish DSM-5 cannabis use disorder diagnosis without clinical follow-up
  • May miss individuals with subtle or intermittent use patterns if consequences are not immediately apparent
  • Performance may vary across populations with different cannabis use norms or patterns of use (e.g., medical versus recreational)
  • Depends on self-report and may be subject to underreporting in legal or social contexts where disclosure carries stigma

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Improved brevity over the original CUDIT (8 versus 10 items) while maintaining strong sensitivity and specificity
  • Free, publicly available screening instrument requiring minimal time and resources
  • Captures multiple dimensions of cannabis use disorder (frequency, dependence signs, consequences, impaired driving)
  • Validated in diverse populations including primary care, addiction treatment, and criminal justice settings
  • Clear cutoff score (≥8) with established diagnostic accuracy for identifying problematic use

Applications

  • Primary care and general practice settings to screen patients for cannabis use disorder during routine health visits or when cannabis use is suspected
  • Emergency department assessment to identify problematic use in patients presenting with acute cannabis-related or other medical/psychiatric complaints
  • Addiction treatment programs for intake screening and risk stratification, particularly in individuals seeking treatment for other substances with concurrent cannabis use
  • Research studies investigating prevalence, predictors, and outcomes of cannabis use disorder across populations and treatment contexts
  • Occupational health screening and workplace wellness programs in safety-sensitive industries where cannabis use may impair performance

How it works

How it works

1

The CUDIT-R comprises 8 items addressing frequency of cannabis use, frequency of heavy use, signs of dependence or tolerance, experience of impaired driving, and psychosocial consequences of use. Items use variable response scales: some items employ a 5-point frequency scale (Never, Less than monthly, Monthly, Weekly, Daily or almost daily), others use yes/no responses, and one item asks about consequences experienced (e.g., health, social, legal problems). The measure is self-administered and takes approximately 2–3 minutes to complete. No training is required to administer or score.

Formula
8 items rated on variable scales: items 1–4 on 0–4 or 0–3 scales; items 5–8 on dichotomous (yes/no) or frequency scales
2

All 8 items are scored and summed to yield a total score ranging from 0 to 32. A cutoff score of 8 or higher indicates hazardous or problematic cannabis use warranting further clinical evaluation or brief intervention. Scores below 8 do not rule out cannabis use but indicate no identified problem use at the threshold for clinical concern. The CUDIT-R does not provide severity subscales; the total score is the primary metric.

Formula
Sum all item responses. Total range 0–32. Cutoff score ≥8 indicates hazardous or harmful cannabis use.
3

A CUDIT-R score at or above 8 indicates the individual is at risk for cannabis use disorder or is experiencing cannabis-related harm and warrants further assessment, brief intervention, or referral to specialized treatment. Scores should be interpreted in clinical context; individuals with lower scores who report significant cannabis-related consequences should still receive intervention. The CUDIT-R is a screening tool and does not provide a diagnosis; positive screens require comprehensive assessment using DSM-5 criteria and detailed substance use history.

Formula
Scores ≥8 suggest problematic cannabis use warranting further assessment. Scores <8 indicate no identified problem use. The CUDIT-R differentiates cannabis use disorder from nonproblematic use.

Common pitfalls

  • Using CUDIT-R as a sole diagnostic instrument without comprehensive clinical assessment; positive screens require DSM-5 evaluation
  • Failing to account for cultural, regional, or age-related variation in cannabis use norms and consequences
  • Assuming a score below 8 indicates no cannabis use problem; clinical judgment may indicate intervention despite negative screening
  • Confusing the CUDIT-R cutoff with absolute thresholds; scores near the cutoff (6–10) warrant clinical review rather than automatic categorization

Frequently asked questions

What is the difference between the original CUDIT and the CUDIT-R?

The CUDIT-R is a revised, shorter version (8 items versus 10) with improved clarity and simplified scoring. Both instruments identify problematic cannabis use, but the CUDIT-R is preferred due to superior brevity and psychometric properties. The cutoff score for the CUDIT-R is ≥8.

Can the CUDIT-R diagnose cannabis use disorder?

No. The CUDIT-R is a screening instrument that identifies individuals at risk for cannabis use disorder or experiencing cannabis-related harm. A positive screen (score ≥8) should be followed by a structured clinical interview using DSM-5 criteria to establish a diagnosis.

How does legal cannabis use affect CUDIT-R interpretation?

Legal status does not alter the validity of the CUDIT-R. Individuals with legal cannabis access may report higher use frequency, but harm and dependence signs remain clinically relevant. CUDIT-R scores should be interpreted the same regardless of local legal status.

Is the CUDIT-R validated for adolescents?

The CUDIT-R was primarily developed and validated in adult populations. Adaptations for adolescents exist but may require modified language or scoring. If screening adolescents, consider using age-appropriate versions or supplementing with clinical interview.

Can the CUDIT-R be used to monitor cannabis use changes during treatment?

Yes. Readministering the CUDIT-R during treatment (monthly or at treatment milestones) can track changes in use frequency and consequences. Declining scores may reflect treatment effectiveness, though behavioral and functional improvements should also be documented.

How does the CUDIT-R compare to DUDIT?

The CUDIT-R is specific to cannabis; DUDIT screens for multiple drug use disorders. Use CUDIT-R for cannabis-specific assessment in individuals with known cannabis use; use DUDIT to screen for broader drug use problems across substance types.

Related methods

Sources

  1. Adamson, S. J., Kay-Lambkin, F. J., Baker, A. L., Lewin, T. J., Thornton, L., Kelly, B. J., & Sellman, J. D. (2010). An improved brief screening instrument for cannabis use disorder. Drug and Alcohol Dependence, 110(1–2), 55–60.

    Open publication reference
    Copied.